Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P122 (ribosomal protein L21 pseudogene 122) is a non-functional, processed pseudogene located in the human genome and annotated in multiple gene databases[2][6][1]. Pseudogenes like RPL21P122 are non-coding DNA sequences derived from functional genes (in this case, ribosomal protein L21, encoded by the RPL21 gene) via gene duplication or retrotransposition. Pseudogenes typically do not encode functional proteins and are not involved in biological processes or disease mechanisms[2][6]. Their presence is a result of evolutionary processes and, except for rare cases of re-activation, they are not considered targets for drug development or clinical diagnostics. If the query intended the *functional* ribosomal protein L21, then the entry is incorrect and should reference the protein encoded by the RPL21 gene, a structural component of the ribosome integral to protein synthesis[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 122 (RPL21P122).